Johnson & Johnson or Procter & Gamble: If I Could Only Own 1 Dividend King for 20 Years, This Is It
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) orProcter & Gamble (NYSE:PG): If someone saving for retirement could hold only one Dividend King for the next 20 years, which one should it be? My pick is Johnson & Johnson, and the gap is wider than the yields suggest. Both stocks trade near 21 times forward earnings (P&G at 21), so valuation is effectively a tie. The decision comes down to three things that matter more to a retiree: dividend coverage, durability and structural risk.
Dividend Track Record and Coverage: J&J Has More Room to Keep Raising
P&G leads on track record. The company has raised its dividend for 70 consecutive years and paid one for 136 consecutive years, compared with J&J’s 64 consecutive years of increases. P&G also yields 2.98%, against 2.12% for J&J.
Coverage tips the scale the other way. J&J’s annualized dividend of $5.36 uses about 46% of the middle of its $11.50 to $11.65 adjusted EPS guidance. P&G’s $4.354 takes about 62% of its $7 core EPS middle. J&J expects free cash flow approaching $21 billion in 2026. P&G produced $15.84 billion in fiscal 2026 and plans to pay out over $10 billion in dividends in fiscal 2027. A long run only lasts a bad year if the payout has room behind it.
Winner: J&J
Business Durability Across Cycles: P&G Wins This Round
People keep buying Tide, Pampers and Charmin in any economy. P&G’s free cash flow rose 12.7% in fiscal 2026 even as operating income fell 3.44%. 9 of 10 categories and all seven regions held or grew organic sales. J&J’s reported results swing with its legal bills. In Q1 2026, net income fell 52.4% on litigation charges and free cash flow dropped 55.4% to $1.5B. Paper towel makers rarely end up in court on that scale.
Winner: P&G
Structural Risk: P&G’s Growth Problem Is Harder to Fix
P&G’s organic sales were flat in its fiscal fourth quarter. Volume, pricing and mix each added nothing. For fiscal 2027, management guides core EPS to $6.89 to $7.11 and expects about a $1.4 billion after-tax drag, or 8% of fiscal 2026 core EPS. When earnings stay flat, a dividend that keeps rising drives the payout ratio higher every year.
J&J’s main exposure is Stelara, which fell 55.7% in Q2 as biosimilars took share. That drug is now a small part of the business. Innovative Medicine chief Jennifer Taubert said on the Q2 call that “Stelara was only 4% of our Innovative Medicine business in the second quarter, and if you exclude that, 96% of our business actually grew over 14%.” Tremfya sales grew 71% to $2 billion, and J&J now has 28 products and platforms each bringing in more than $1 billion a year. Stelara’s decline is already absorbed. P&G’s cost pressure is still ahead of it.
Winner: J&J
Verdict: Johnson & Johnson Is My 20-Year Dividend King
J&J wins two of three, and the long-run record agrees. Its split-adjusted share price rose 180.5% over ten years, while P&G’s rose 116.7%. Its most recent dividend increase was 3.1%, a bit ahead of P&G’s 3%, and it starts from a lower payout ratio. Management is aiming “double-digit growth by the end of the decade.” That gives J&J more room to raise its dividend for 20 years than a company guiding to in-line to +3% EPS growth.
P&G is the better fit for one kind of investor: a retiree who needs the extra yield today and values a 136-year payment record above everything else. Over a 20-year horizon, J&J has the stronger dividend profile (we ranked ten Dividend Kings by valuation right now in a free report that you can grab here).
Here is what would break that thesis. Litigation charges were $330M in Q1 2026 and $854M in Q4 2025. If those keep rising, or if oncology falls short of its goal of more than $50 billion in sales by 2030, the coverage edge shrinks quickly. The events to track are the DePuy Synthes separation planned for mid-2027 and the size of J&J’s next annual dividend increase.
Contact [email protected] for any questions or corrections.







